Product Data Sheet

Eptifibatide

Cat. No.: B3490
CAS No.: 188627-80-7
Formula: C35H49N11O9S2
M.Wt: 831.96
Synonyms:
Target:
Pathway:
Storage: Store at -20°C



Solvent & Solubility

In Vitro

≥28.7 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

Preparing Stock Solutions

Concentration \ Mass / Solvent	1mg	5mg	10mg
1 mM	1.2020 mL	6.0099 mL	12.0198 mL
5 mM	0.2404 mL	1.2020 mL	2.4040 mL
10 mM	0.1202 mL	0.6010 mL	1.2020 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Glycoprotein (GP) IIb/IIIa inhibitor
IC_{50} & Target	

In Vitro

Cell Viability Assay

Cell Line:	Activated platelets and leukocytes
Preparation method:	The solubility of this compound in DMSO is >28.7 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

	Reacting conditions:	0.0625-1.5 w g/ml
	Applications:	Eptifibatide dose-dependently enhanced (0.0625-1.5 w g/ml) both collagen-induced platelet-monocyte (P/M) formation and monocyte TF expression with maximum enhancement about 60 and 120%, respectively, at 0.5 w g/ml eptifibatide. Eptifibatide had only a minor effect on platelet-neutrophil (P/N) formation and no effect on neutrophil TF expression. Eptifibatide dose-dependently reduced ADP, collagen, and thrombin-induced platelet aggregation (IC50 = 16-27 mg/mL), dense granule secretion (IC50 = 22-31 mg/mL) and lysosome secretion (IC50 = 25-50 mg/mL). Eptifibatide (8 mg/mL) together with bivalirudin (70 ng/mL, a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL).
In Vivo	**Animal experiment**	
	Applications:	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Scholz T, Zhao L, Temmler U, et al. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro[J]. Platelets, 2002, 13(7): 401-406.
[2]. Ciborowski M, Tomasiak M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets[J]. Acta poloniae pharmaceutica, 2008, 66(3): 235-242.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com